- Home
- COHU vs URGN Comparison
COHU vs URGN Comparison
Compare COHU & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHU
- URGN
- Stock Information
- Founded
- COHU 1947
- URGN 2004
- Country
- COHU United States
- URGN United States
- Employees
- COHU N/A
- URGN N/A
- Industry
- COHU Electrical Products
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- COHU Industrials
- URGN Health Care
- Exchange
- COHU Nasdaq
- URGN Nasdaq
- Market Cap
- COHU 885.9M
- URGN 904.0M
- IPO Year
- COHU N/A
- URGN 2017
- Fundamental
- Price
- COHU $20.34
- URGN $18.88
- Analyst Decision
- COHU Buy
- URGN Strong Buy
- Analyst Count
- COHU 6
- URGN 8
- Target Price
- COHU $28.20
- URGN $28.50
- AVG Volume (30 Days)
- COHU 402.0K
- URGN 1.0M
- Earning Date
- COHU 10-30-2025
- URGN 11-05-2025
- Dividend Yield
- COHU N/A
- URGN N/A
- EPS Growth
- COHU N/A
- URGN N/A
- EPS
- COHU N/A
- URGN N/A
- Revenue
- COHU $393,941,000.00
- URGN $94,238,000.00
- Revenue This Year
- COHU $13.11
- URGN $35.60
- Revenue Next Year
- COHU $11.48
- URGN $129.54
- P/E Ratio
- COHU N/A
- URGN N/A
- Revenue Growth
- COHU N/A
- URGN 10.85
- 52 Week Low
- COHU $12.57
- URGN $3.42
- 52 Week High
- COHU $29.42
- URGN $21.02
- Technical
- Relative Strength Index (RSI)
- COHU 55.17
- URGN 51.50
- Support Level
- COHU $19.03
- URGN $18.17
- Resistance Level
- COHU $20.63
- URGN $20.20
- Average True Range (ATR)
- COHU 0.74
- URGN 0.90
- MACD
- COHU -0.03
- URGN -0.24
- Stochastic Oscillator
- COHU 74.43
- URGN 34.98
About COHU Cohu Inc.
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection).
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.